Apellis Pharmaceuticals, Inc. (APLS) Stock Price, Financials & Summary

Price chart

Apr 16Apr 21Apr 24Apr 29May 4May 7May 12May 15

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

30.0x

Market Cap

$5.25B

MomentumView details →

1D Return

+0.00%

YTD Return

+63.34%

RSI (14)

84.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

30.0x

Market Cap

$5.25B

RSI (14)

84.5

MomentumView details →

1D Return

+0.00%

YTD Return

+63.34%

SummaryUpdated Mar 1, 2026

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company founded in 2009 and based in Waltham, Massachusetts. The company went public in November 2017 and focuses on developing and commercializing therapeutic compounds that target the complement system, a critical component of the body's immune defense mechanism. Apellis has successfully transitioned from a development-stage company to a commercial enterprise with two approved products generating significant revenue, while maintaining a robust pipeline of complement-based therapies for various autoimmune and inflammatory diseases.

Ask drillr about Apellis Pharmaceuticals, Inc. →

ProfitabilityView details →

Gross Margin

90.12%

Net Margin

12.06%

EBITDA Margin

16.03%

ROE (TTM)

32.12%

ROA (TTM)

12.31%

Asset Turnover

1.02x

GrowthView details →

Revenue YoY

+42.46%

EPS YoY

+159.22%

FCF YoY

+549.16%

Revenue CAGR 3Y

+136.98%

EPS CAGR 3Y

+111.25%

EBITDA YoY

+200.61%

EarningsView details →

EPS (Actual)

$0.15

EPS Surprise

139.47%

Beats (12Q)

7/12

Next Q EPS Est

—

Avg Surprise (4Q)

62.06%

Rev Surprise

27.47%

Capital & dividendView details →

Debt/Equity

1.15x

Current Ratio

3.63x

Quick Ratio

3.16x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.11B

Net Income (TTM)

133.27M

Op. CF (TTM)

37.77M

Latest newsMore news →

Biogen completed its $5.6 billion acquisition of Apellis and is now integrating the biotech by terminating most of Apellis' research programs and eliminating a small number of research roles.70d ago

Similar companies

博拓生物688767.SH CRISPR Therapeutics AGCRSP Abbisko Cayman Limited02256.HK Jacobio Pharmaceuticals Group Co., Ltd.01167.HK 三力制药603439.SH Erasca, Inc.ERAS Find similar companies →

Latest newsMore news →

The U.S. Court of Appeals for the First Circuit affirmed the dismissal of a putative securities class action against Apellis Pharmaceuticals and its CEO, holding that the company's statements about clinical trial results were not actionable half-truths.2d ago Biogen completed its $5.6 billion acquisition of Apellis and is now integrating the biotech by terminating most of Apellis' research programs and eliminating a small number of research roles.70d ago